#Switzerland #Lundbeck #Baar #Swixx BioPharma #CNS Therapy

Swixx BioPharma Expands Its Market Reach through Strategic Alliance with Lundbeck

Swixx BioPharma AG, a prominent global platform committed to enhancing access to innovative pharmaceuticals, has recently announced an important strategic agreement with H. Lundbeck A/S, a biopharmaceutical company that specializes in brain health. This alliance is set to significantly transform the Central Nervous System (CNS) therapy market across several regions including Southeast Europe, Turkey, and Latin America.

Overview of the Agreement

On September 10, 2025, Swixx BioPharma revealed their latest partnership which appoints them as the distributor and commercial partner for Lundbeck's comprehensive range of CNS products. This portfolio encompasses treatments for psychiatric disorders including major depressive episodes and schizophrenia, alongside a new therapy aimed at migraine prophylaxis. As part of the deal, Swixx is expected to facilitate not just distribution, but also support for physicians and patients to access both existing and new medications from Lundbeck's lineup.

Jean-Michel Lespinasse, CEO of Swixx, expressed their pride in being selected by Lundbeck, stating, “We are truly honored to be selected as a strategic partner across three regions. This partnership underscores the evolving trend within the pharma landscape towards outsourcing in emerging markets, which we believe is crucial for future growth.” This partnership will empower Swixx to boost its operations at a larger scale, while making a strong mark in the CNS therapeutic field. Furthermore, it promises career opportunities for current Lundbeck employees who wish to join Swixx, ensuring business continuity and the preservation of valuable expertise.

The Significance of the Partnership

The collaboration is not simply transactional; it aims to enhance value creation through leveraging local market knowledge paired with Lundbeck's established reputation in CNS therapies. Dr. Dezso Martha, COO for Swixx's European markets, noted that carrying forward Lundbeck's legacy in the CNS sector is a pivotal goal. In light of this, Swixx is set to establish a dedicated CNS Business Unit designed specifically to strengthen its capabilities in this area.

Moreover, Dr. Marek Vasicek, COO of International Markets, added that the partnership would support their ambition to expand both mature and innovative product lines within the therapy sector. This collaboration is positioned strategically to facilitate access to Lundbeck's offerings to a broader patient demographic, making it a win-win situation for all parties involved.

Impact on Latin America and Future Growth

In Latin America, Swixx will be focusing on key markets such as Argentina, Chile, Colombia, and Mexico, which have been identified as strategic territories. Pascal Forget, Executive Regional General Manager for LATAM, emphasized that this partnership will further solidify their standing in the CNS domain across the region. The inclusion of Lundbeck’s talent within Swixx is a promising step towards enriching operational expertise leading to accelerated growth.

According to Charl van Zyl, President and CEO of Lundbeck, this decision to partner with Swixx came after meticulous consideration of their strong regional presence and cultural alignment with Lundbeck's core values. With more than 70 years of experience, Lundbeck focuses exclusively on improving brain health, an objective they strive to achieve through innovative solutions to complex neurological issues.

Conclusion

The newly inked deal between Swixx BioPharma and Lundbeck marks a significant milestone in the pharmaceutical industry, especially for CNS therapies. It capitalizes on Swixx's expansive commercial platform and expertise in local markets, combined with Lundbeck's established reputation in the CNS space. By facilitating enhanced access to these critical medications, both companies aim to create a lasting positive impact on patient health across several crucial regions. Moving forward, this partnership is poised to set a precedent for how pharmaceutical companies can collaborate to achieve broader goals in patient care and treatment accessibility.

For more information about Swixx and Lundbeck, you can visit their respective websites.